Weight-Loss drugs may boost your sex drive, study hints

NCT ID NCT05598008

Completed Symptom relief Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether GLP-1 analogues (like Ozempic or Wegovy) combined with lifestyle changes can improve sexual desire in overweight or obese men and women. 85 participants were followed to measure changes in sexual thoughts, activity, and overall sexual health. The goal is to understand how these popular weight-loss drugs might affect sexuality beyond just weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 analogues (e.g., liraglutide, semaglutide)
What this could lead to: If successful, this could show that GLP-1 drugs help improve sexual desire in overweight or obese people, offering a new benefit of these medications.
What could go wrong: This is a small, completed study with only 85 participants. Results may not apply to everyone, and the open-label design (no placebo) can bias outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Motor Activity Obesity obesity disorder Sexuality

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEXUAL DESIRE

Contacts and locations

Locations

University Hospital Basel, Endocrinology, Diabetes and Metabolism

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.